ERNA
Ernexa Therapeutics Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Sell
-48/100
Last price
2.24
▲ 0.01 (0.22%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
2.21
Prev close
2.24
Day high
2.32
Day low
2.15
Volume
8.81K
Market cap
$3.66M
P/E (TTM)
—
52W range
2.15 – 71.50
Day trading desk
Gap from prior close
-1.45%
Prior close 2.24
VWAP
2.26
-1.05% from price
Relative volume
0.02×
Quiet session
Session range
7.90%
2.15 – 2.32
Position in range
53%
Mid range
ATR (14D)
0.34
15.24% of price
Prior day high
2.96
PDH
Prior day low
2.20
PDL
Bid / ask spread
—
Quote not published
Session volume
8.80K
Avg 462.76K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-30.00%
-31.9%
1M
-46.54%
-48.0%
3M
-62.23%
-65.6%
6M
-59.27%
-74.3%
YTD
-92.53%
-106.5%
1Y
-93.41%
-109.1%
3Y
-99.73%
-181.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ERNA open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+45.28M
Net buying
Buy transactions
42
46.25M shares
Sell transactions
10
962.25K shares
Net transactions
+52
Buys less sells
Sell : buy shares
0.0 : 1
Mixed
Insider-held shares
482.02K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Feb 10, 26 | CHERINGTON CHARLES Beneficial Owner of more than 10% of a Class of Security |
BUY | 4.00M | $2.00M | Direct |
| Jun 20, 25 | GURROLA SANDRA M Officer |
— | 30 | — | Direct |
| Jun 9, 25 | CHERINGTON CHARLES Beneficial Owner of more than 10% of a Class of Security |
BUY | 21.24M | $2.22M | Direct |
| Apr 2, 25 | CHERINGTON CHARLES Beneficial Owner of more than 10% of a Class of Security |
BUY | 3.77M | $394.17K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CHERINGTON CHARLES |
Beneficial Owner of more than 10% of a Class of Security | 6.78M | Purchase |
GURROLA SANDRA M |
Officer | 110 | Conversion of Exercise of derivative security |
Fundamentals
Market cap$3.66M
Enterprise value$-1.03M
Revenue (TTM)—
Gross profit—
EBITDA$-11.69M
Net income$-12.27M
EPS (TTM)$-13.63
Free cash flow$-5.93M
Total cash$5.03M
Total debt$349.00K
Book value / share$2.73
Shares outstanding1.63M
Float1.22M
Short % of float1.20%
Dividend yield0.00%
Beta (5Y)2.65
Valuation & profitability ratios
Trailing P/E—
Forward P/E-0.23
PEG ratio—
Price / sales—
Price / book0.82
EV / revenue—
EV / EBITDA0.09
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-320.72%
Return on assets-105.56%
Debt / equity10.91
Current ratio2.01
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $582.00K | $68.00K | $0 | -100.0% |
| Operating revenue | $0 | $582.00K | $68.00K | $0 | -100.0% |
| Cost of revenue | $0 | $96.00K | $236.00K | $0 | -100.0% |
| Gross profit | $0 | $486.00K | -$168.00K | $0 | -100.0% |
| Research & development | $4.16M | $4.60M | $5.92M | $10.39M | -9.7% |
| Selling, general & admin | $5.16M | $13.13M | $14.59M | $16.55M | -60.7% |
| Total operating expense | $9.32M | $17.74M | $20.51M | $26.95M | -47.5% |
| Operating income | -$9.32M | -$17.25M | -$20.68M | -$26.95M | +46.0% |
| Net interest income | $56.00K | -$6.50M | -$476.00K | -$30.00K | +100.9% |
| Pre-tax income | -$14.13M | -$44.51M | -$21.67M | -$24.53M | +68.3% |
| Tax provision | -$45.00K | $30.00K | -$3.00K | $45.00K | -250.0% |
| Net income | -$14.08M | -$44.54M | -$21.67M | -$24.58M | +68.4% |
| Net income to common | -$14.10M | -$44.55M | -$21.68M | -$24.59M | +68.4% |
| Basic EPS | -56.00 | -1,224.00 | -1,530.00 | -3,022.50 | +95.4% |
| Diluted EPS | -56.00 | -1,224.00 | -1,530.00 | -3,022.50 | +95.4% |
| EBIT | -$14.10M | -$37.76M | -$21.06M | -$24.50M | +62.7% |
| EBITDA | -$13.84M | -$36.12M | -$19.93M | -$24.01M | +61.7% |
| Basic shares | 252.28K | 36.40K | 14.17K | 8.14K | +593.1% |
| Diluted shares | 252.28K | 36.40K | 14.17K | 8.14K | +593.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.88M | $1.73M | $7.58M | $11.45M | — | +9.0% |
| Cash & short-term investments | $1.88M | $1.73M | $7.58M | $11.45M | — | +9.0% |
| Accounts receivable | — | — | — | — | $684.00K | — |
| Total current assets | $3.13M | $2.35M | $9.60M | $13.68M | — | +33.2% |
| Property, plant & equipment | $547.00K | $755.00K | $33.27M | $1.27M | — | -27.5% |
| Goodwill & intangibles | $2.04M | $2.04M | $2.04M | $2.04M | — | 0.0% |
| Total assets | $5.83M | $5.27M | $49.13M | $22.28M | — | +10.7% |
| Total current liabilities | $3.11M | $2.94M | $6.57M | $7.65M | — | +6.0% |
| Current debt | — | — | — | $1.75M | — | — |
| Long-term debt | — | — | $6.77M | $1.21M | — | — |
| Total debt | $490.00K | $684.00K | $41.84M | $1.18M | — | -28.4% |
| Total liabilities | $3.43M | $3.57M | $46.90M | $10.17M | — | -3.8% |
| Retained earnings | -$245.64M | -$231.54M | -$186.98M | -$165.30M | — | -6.1% |
| Shareholder equity | $2.40M | $1.70M | $2.23M | $12.11M | — | +41.2% |
| Working capital | $20.00K | -$586.00K | $3.03M | $6.03M | — | +103.4% |
| Net tangible assets | $357.00K | -$343.00K | $189.00K | $10.06M | — | +204.1% |
| Shares issued | 314.16K | 137.03K | 14.43K | 13.67K | — | +129.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$14.08M | -$44.54M | -$21.67M | -$24.58M | — | +68.4% |
| Depreciation & amortisation | $263.00K | $1.64M | $1.12M | $497.00K | — | -83.9% |
| Stock-based compensation | $1.50M | $1.52M | $1.24M | $2.94M | — | -1.6% |
| Change in working capital | -$51.00K | -$1.98M | -$2.12M | $3.71M | — | +97.4% |
| Operating cash flow | -$7.02M | -$15.84M | -$20.41M | -$20.98M | — | +55.7% |
| Capital expenditure | -$37.00K | -$369.00K | -$19.00K | -$297.00K | — | +90.0% |
| Investing cash flow | -$37.00K | -$365.00K | -$19.00K | -$47.00K | — | +89.9% |
| Dividends paid | — | $0 | -$16.00K | -$16.00K | -$8.00K | — |
| Financing cash flow | $7.21M | $6.26M | $16.56M | $19.58M | — | +15.2% |
| Free cash flow | -$7.05M | -$16.20M | -$20.43M | -$21.27M | — | +56.5% |
| End cash position | $1.88M | $1.73M | $11.67M | $15.54M | — | +9.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Cost of revenue | — | $0 | $0 | $0 | $0 | $0 | — |
| Gross profit | — | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $2.79M | $1.92M | $676.00K | $1.03M | $1.14M | — | +45.8% |
| Selling, general & admin | $1.31M | $1.63M | $1.42M | $958.00K | $1.36M | — | -19.6% |
| Total operating expense | $4.10M | $3.55M | $2.09M | $1.99M | $2.50M | — | +15.7% |
| Operating income | -$4.10M | -$3.55M | -$2.09M | -$1.99M | -$2.50M | — | -15.7% |
| Net interest income | $55.00K | $44.00K | $20.00K | $31.00K | $0 | — | +25.0% |
| Pre-tax income | -$4.01M | -$5.55M | -$1.56M | -$1.23M | -$3.14M | — | +27.7% |
| Tax provision | $0 | -$40.00K | -$62.00K | $6.00K | $3.00K | — | +100.0% |
| Net income | -$4.01M | -$5.51M | -$1.50M | -$1.24M | -$3.14M | — | +27.2% |
| Net income to common | -$4.02M | -$5.51M | -$1.51M | -$1.24M | -$3.15M | — | +27.0% |
| Basic EPS | -3.40 | -6.95 | — | -3.75 | -15.19 | -57.76 | +51.1% |
| Diluted EPS | -3.40 | -6.95 | — | -3.75 | -15.19 | -57.76 | +51.1% |
| EBIT | -$4.10M | -$3.55M | -$6.88M | -$1.99M | -$2.50M | — | -15.7% |
| EBITDA | -$4.06M | -$3.46M | -$6.81M | -$1.92M | -$2.45M | — | -17.3% |
| Basic shares | 1.18M | 792.00K | — | 329.04K | 207.00K | 142.00K | +49.4% |
| Diluted shares | 1.18M | 792.00K | — | 329.04K | 207.00K | 142.00K | +49.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $5.03M | $9.18M | $1.88M | $3.05M | $4.32M | — | -45.2% |
| Cash & short-term investments | $5.03M | $9.18M | $1.88M | $3.05M | $4.32M | — | -45.2% |
| Total current assets | $5.89M | $10.00M | $3.13M | $3.38M | $4.79M | — | -41.0% |
| Property, plant & equipment | $396.00K | $437.00K | $547.00K | $633.00K | $631.00K | — | -9.4% |
| Goodwill & intangibles | $0 | $0 | $2.04M | $2.04M | $2.04M | — | — |
| Total assets | $6.32M | $10.54M | $5.83M | $6.17M | $7.58M | — | -40.1% |
| Total current liabilities | $2.93M | $3.46M | $3.11M | $2.14M | $2.65M | — | -15.2% |
| Current debt | — | — | — | — | — | $2.25M | — |
| Total debt | $349.00K | $389.00K | $490.00K | $552.00K | $593.00K | — | -10.3% |
| Total liabilities | $3.12M | $3.68M | $3.43M | $2.60M | $3.14M | — | -15.4% |
| Retained earnings | -$255.16M | -$251.14M | -$245.64M | -$244.13M | -$242.88M | — | -1.6% |
| Shareholder equity | $3.20M | $6.86M | $2.40M | $3.57M | $4.44M | — | -53.3% |
| Working capital | $2.96M | $6.54M | $20.00K | $1.24M | $2.14M | — | -54.7% |
| Net tangible assets | $3.20M | $6.86M | $357.00K | $1.53M | $2.40M | — | -53.3% |
| Shares issued | 1.17M | 1.17M | 314.16K | 313.95K | 299.32K | — | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$4.01M | -$5.51M | -$1.50M | -$1.24M | -$3.14M | +27.2% |
| Depreciation & amortisation | $44.00K | $86.00K | $69.00K | $70.00K | $55.00K | -48.8% |
| Stock-based compensation | $320.00K | $309.00K | $333.00K | $293.00K | $368.00K | +3.6% |
| Change in working capital | -$490.00K | $707.00K | -$50.00K | $279.00K | -$461.00K | -169.3% |
| Operating cash flow | -$4.15M | -$2.26M | -$1.15M | -$1.27M | -$2.53M | -83.4% |
| Capital expenditure | -$3.00K | -$2.00K | -$15.00K | — | — | -50.0% |
| Investing cash flow | -$3.00K | -$2.00K | -$15.00K | -$22.00K | $0 | -50.0% |
| Dividends paid | — | — | — | $0 | — | — |
| Financing cash flow | $6.00K | $9.56M | $0 | $26.00K | $4.93M | -99.9% |
| Free cash flow | -$4.16M | -$2.27M | -$1.16M | -$1.29M | -$2.53M | -83.4% |
| End cash position | $5.03M | $9.18M | $1.88M | $3.05M | $4.32M | -45.2% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -3.30 | -3.40 | -3.0% |
| Mar 2026 | -1.95 | -6.95 | -256.4% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -3.84 | 1 | $0 | — |
| Next quarter | -4.76 | 1 | $0 | — |
| Current year | -18.02 | 1 | $0 | — |
| Next year | -1.86 | 1 | $0 | 0.0% |
Analyst targets & ownership
Mean target$30.00
High target$30.00
Low target$30.00
Implied upside1239.29%
Analyst count1
ConsensusNONE
Strong buy / Buy0 / 1
Hold0
Sell / Strong sell0 / 0
Held by insiders29.53%
Held by institutions2.18%
Institutions holding10
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
3.00
-25.33% from price
SMA 20
3.47
-35.49% from price
SMA 50
3.98
-43.68% from price
SMA 100
5.67
-60.51% from price
SMA 200
9.83
-77.20% from price
EMA 12
3.01
-25.63% from price
EMA 26
3.50
-36.06% from price
EMA 50
4.10
-45.31% from price
RSI (14)
18.8
Oversold
MACD (12,26,9)
-0.49
Hist -0.12
ATR (14)
0.34
15.24% of price
Realised vol 30D
73.2%
Annualised
Bollinger upper
4.65
20, 2σ
Bollinger lower
2.30
20, 2σ
50 / 200 cross
Death
3.98 vs 9.83
Trend bias
Below 200
-77.20%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.61
Less volatile than market
Correlation to SPY
0.05
Largely independent
Realised vol 30D
73.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-95.2%
Peak to trough
Max drawdown 5Y
-100.0%
Peak to trough
ATR 14
0.34
15.24% of price
Beta (reported)
2.65
5Y monthly, from filing
Short interest
Shares short
14.36K
Prior 24.66K
Change vs prior
-41.8%
Shorts covering
% of float
1.20%
Normal
% of shares out
0.88%
Against total outstanding
Days to cover
0.3
Liquid
Float
1.22M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:25
Split dateMay 4, 2026
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-16
Periodic Financial Reports
10-Q · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-07-02
Corporate Changes & Voting Matters
8-K · 2026-06-26
Periodic Financial Reports
10-Q · 2026-05-11
Corporate Changes & Voting Matters
8-K · 2026-05-04
Proxy Statements
DEF 14C · 2026-04-13
Proxy Statements
PRE 14C · 2026-04-01
Headlines
Ernexa Therapeutics’ ERNA-101 Selected for Flash Talk Presentation at Nature Conferences’ Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center
GlobeNewswire · 1d ago
Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic
GlobeNewswire · 6d ago
Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND
GlobeNewswire · 7d ago
Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy
GlobeNewswire · 8d ago
Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors
GlobeNewswire · 20d ago
Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human Dosing
GlobeNewswire · 22d ago
Ernexa Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · 23d ago
Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
GlobeNewswire · 41d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.